Extended Data Fig. 1: Effect of empagliflozin versus placebo on changes in NYHA functional class in patients with LVEF ≥ 50%. | Nature Medicine

Extended Data Fig. 1: Effect of empagliflozin versus placebo on changes in NYHA functional class in patients with LVEF ≥ 50%.

From: Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Extended Data Fig. 1

Odds ratios were calculated using a multivariable Cox regression model. Data are presented as point estimates and 95% CIs with two-sided P values. No adjustments for multiple testing were made. Patients treated with empagliflozin had higher odds of improving NYHA class at week 52 (odds ratio 1.32 [95% CI: 1.10–1.56]; P = 0.0033) and lower odds of worsening NYHA class at week 52 (odds ratio 0.74 [95% CI: 0.54–1.01]; P = 0.0606). LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Back to article page